Drugs / SUTIDIAZINE
SUTIDIAZINE
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05206201 | Aug 2021 → Jan 2022 | malaria | Zydus Lifesciences Limited | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05911828 Comparator | Aug 2024 → Feb 2025 | Plasmodium falciparum malaria | Zydus Lifesciences Limited | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SUTIDIAZINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4284447 ↗ |
| Known as | MMV253 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4284447 ↗ |
| Known as | Sutidiazina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4284447 ↗ |
| Known as | ZY-19489 | “ZY-19489 Administered Via Oral Route” NCT05206201 ↗ |
| Modality | Small molecule | “a triaminopyrimidine” NCT05911828 ↗ |
| Route | Oral | “ZY-19489 Administered Via Oral Route” NCT05206201 ↗ |